Clinical Trial Update: Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing the efficacy and safety of rifaximin dosed twice daily for diarrhea-associated irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED